GSK (GSK) and LTZ Therapeutics announced a strategic research collaboration to advance the development of novel myeloid cell engagers, MCEs, to address significant unmet need in oncology. The research collaboration aims to develop up to four potential first-in-class MCE therapies targeting haematologic cancers and solid tumors. The agreement grants GSK an exclusive option to license worldwide development and commercial rights for these pre-clinical therapies. Under the terms of the agreement, LTZ will receive an upfront payment of $50 million and is eligible to receive success-based preclinical, clinical, regulatory and commercial milestone payments, plus tiered royalties on global net sales of commercialized products resulting from the collaboration.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- FDA appoints Richard Pazdur as Director of CDER
- Cogent upgraded to Buy at Stifel after ‘overwhelmingly positive’ GIST data
- AN2 Therapeutics announces tuberculosis collaboration agreement with GSK
- GSK price target raised to 1,500 GBp from 1,400 GBp at JPMorgan
- GSK presents data from liver pipeline at AASLD 2025